Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis
Abstract
Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-α, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis.Downloads
Download data is not yet available.
Statistics
- Abstract views: 725
- PDF: 859
How to Cite
Bellissimo, S., Ferrucci, M., Gallo, A., & Stisi, S. (1). Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis. Reumatismo, 59(3), 240-243. https://doi.org/10.4081/reumatismo.2007.240
Copyright (c) 1970 S. Bellissimo, M.G. Ferrucci, A. Gallo, S. Stisi

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.